• TRADE NAME: Toviaz (Pfizer)
  • INDICATIONS: Overactive bladder syndrome; urinary incontinence, urgency and frequency
  • CLASS: Muscarinic antagonist
  • HALF-LIFE: 7 hours; 4 hours (oral)

Contra-indicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.

Please login to view the rest of this drug profile.

    DRUG REVIEW ARTICLE

    Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fesoterodine in the Informa Healthcare journal Expert Opinion on Drug Safety.

    (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric